


Quality Innovation Network -Quality Improvement Organizations CENTERS FOR MEDICARE & MEDICAID SERVICES IQUALITY IMPROVEMENT & INNOVATION GROUP

## 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar 13<sup>®</sup>)



Matanock, A., Lee, G., Gierke, R., Kobayashi, M., Leidner, A., & Pilishvili, T. (2019). "Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged  $\geq$ 65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices." *MMWR. Morbidity and mortality weekly report*, 68(46), 1069–1075. <u>https://doi.org/10.15585/mmwr.mm6846a5</u>

PneumoRecs VaxAdvisor: Vaccine Provider App | CDC accessed 3/18/2021

This material was prepared by the IPRO QIN-QIO, a collaboration of Healthcentric Advisors, Qlarant and IPRO, serving as the Medicare Quality Innovation Network-Quality Improvement Organization for the New England states, NY, NJ, OH, DE, MD, and the District of Columbia, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents do not necessarily reflect CMS policy.Publication No. 12SOW-IPRO-QIN-T3-AA-21-381 v.4 5/27/2021